A clinical evaluation showed Ocean Dx’s rapid sepsis assay detected more than 1,000 bacterial species directly from whole blood with 100% sensitivity and 100% specificity versus reference blood cultures, delivering results in about five hours. The test also tripled the number of infections identified in the study, suggesting potential to accelerate pathogen ID and guide early therapy. If larger, multi‑center validations confirm performance, the assay could shift sepsis diagnostics toward culture‑independent, rapid identification — enabling earlier targeted antimicrobial therapy. Regulatory clearance and cost‑effectiveness analyses will determine clinical uptake.